Sort
10,766 grants matching “checkpoint inhibitor”
Novel DNA damage response therapeutics targeting replication protein A
$491,249John J Turchi · Indiana University Indianapolis · R01 · FY2025 · CA
Renalase inhibition for treatment of unresectable melanoma
$491,209Harriet M Kluger · Yale University · R01 · FY2018 · CA
The Adenosinergic Pathway in Tumor-derived Exosomes
$491,088Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R01 · FY2022 · CA
Microbiota-Immune Interactions in CTLA-4 Antibody Blockade-Induced Colitis
$490,725Gabriel Nunez · University Of Michigan At Ann Arbor · R01 · FY2024 · DK
Investigating the roles of extracellular cGAMP and harnessing it for cancer treatment
$490,632Lingyin Li · Stanford University · R01 · FY2022 · CA
Investigating the roles of extracellular cGAMP and harnessing it for cancer treatment
$490,632Aaron F Straight · Stanford University · R01 · FY2023 · CA
Fractionated photoimmunotherapy to harness low-dose immunostimulation in ovarian cancer
$490,448Bryan Quilty Spring · Northeastern University · U01 · FY2024 · CA
Renalase inhibition for treatment of unresectable melanoma
$490,257Harriet M Kluger · Yale University · R01 · FY2017 · CA
Investigating multifactorial beta-catenin activation in hepatocellular cancers
$490,219Xin Chen · University Of Hawaii At Manoa · R01 · FY2025 · CA
FOXA1 regulates cytokine signaling and immune landscape in prostate cancer through ARID1A
$490,082Jindan Yu · Emory University · R01 · FY2024 · CA
Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
$490,061Triparna Sen · Icahn School Of Medicine At Mount Sinai · R01 · FY2022 · CA
Targeting replication stress signaling to overcome immune evasion in small cell lung cancer
$490,061Triparna Sen · Icahn School Of Medicine At Mount Sinai · R01 · FY2025 · CA
Randomized Trial of Stepped Palliative Care versus Early Integrated Palliative Care in Patients with Advanced Lung Cancer
$489,932Jennifer Temel · Massachusetts General Hospital · R01 · FY2019 · CA
Regulation of Chromosome Segregation in Human Cells
$489,753Prasad V Jallepalli · Sloan-Kettering Inst Can Research · R01 · FY2020 · GM
Regulation of Chromosome Segregation in Human Cells
$489,753Prasad V Jallepalli · Sloan-Kettering Inst Can Research · R01 · FY2021 · GM
Regulation of Chromosome Segregation in Human Cells
$489,753Prasad V Jallepalli · Sloan-Kettering Inst Can Research · R01 · FY2019 · GM
Racial differences in Immunogenetic Tumorigenesis of Head and Neck Squamous Cell Carcinoma
$489,635David Sidransky · Johns Hopkins University · R01 · FY2022 · CA
Project 4: Translation and preclinical studies of a personalized pancreas cancer vaccine
$489,305William E Gillanders · Washington University · P50 · FY2016 · CA
Small molecule inhibitors as a new approach to study human RAD51 recombinase
$489,218Alexander V Mazin · Drexel University · R01 · FY2015 · CA
Function of Wdfy4 in cross-presentation and immunity
$489,211Kenneth M. Murphy · Washington University · R01 · FY2023 · AI
Potentiating a systemic antitumor response by interstitial localized ablative immunotherapy to synergize with immune checkpoint therapy for metastatic pancreatic tumors
$489,114Wei R. Chen · University Of Oklahoma · R01 · FY2025 · CA
Targeting the innate immune response in HNSCC
$488,418Judith A. Varner · University Of California, San Diego · R01 · FY2024 · DE
Overcoming vaccine-associated hypoxia with advanced biomaterials to enhance cancer immunotherapy
$488,344Sidi A Bencherif · Northeastern University · R01 · FY2021 · EB
OST Inhibition in NSCLC
$487,978Joseph N Contessa · Yale University · R01 · FY2021 · CA
OST Inhibition in NSCLC
$487,978Joseph N Contessa · Yale University · R01 · FY2020 · CA